Pages Asociados
November 2, 2026
Pages Asociados was listed as a victim on the leak site of the thegentlemen ransomware group; the attack is estimated to have taken place on 2026-11-02. Country: Venezuela (Bolivarian Republic of). Website: pages.com.ve. pages.com.ve Pages Asociados C.A. is a Venezuelan engineering and consulting firm founded in 1972 in Caracas with over 52 years of experience in civil, structural, mechanical and electrical engineering. It operates its own geotechnical and materials testing laboratory, covering soil mechanics, concrete, asphalt and steel testing alongside field investigation services. With offices in Caracas, Maracaibo, Puerto Ordaz and Barinas, it serves the oil and gas, transport, energy and industrial sectors across Venezuela. Key projects include oil terminals for PDVSA, highways, bridges, hydropower plants and port infrastructure. Led by the Pages family across multiple generations, it employs around 200 to 500 engineers and technicians depending on project load. Key strengths are 52 years of market presence, in-house laboratory capabilities and full-service engineering from design through construction supervision and project management.
KABS Pharmaceutical Services
November 2, 2026
KABS Pharmaceutical Services was listed as a victim on the leak site of the thegentlemen ransomware group; the attack is estimated to have taken place on 2026-11-02. Sector: Healthcare. Country: United Kingdom of Great Britain and Northern Ireland. Website: kabs.com. kabs.com Revenue $27.2 Million KABS Laboratories is a Canadian pharmaceutical CDMO founded in 1997 in Saint-Hubert, Quebec by Dr. Jean-Simon Blais and Dr. Grard Akinocho, with 150+ specialists serving clients in 28 countries. It is a WHO prequalified Quality Control Laboratory audited by Health Canada, USFDA and EU QPs, offering aseptic manufacturing from 100 to 100,000 vials per batch. In 2021 it received CAD 54.2 million from Canada's Strategic Innovation Fund to expand fill-and-finish to 30 million vials per year and build a bioprocessing plant for monoclonal antibodies. Through joint venture MendeliKABS it developed MDK-Nitisinone, an orphan drug for tyrosinemia type 1, priced 10 times lower than the Swedish competitor and approved in Europe, UK, Brazil, China and Algeria. The company also runs an African quality control office in Benin.